Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $3 | $5 |
| SG&A Expenses | $2 | $2 | $3 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $3 | $5 |
| Operating Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $0 | $2 |
| Pre-Tax Income | -$1 | -$2 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.083 | -0.11 | -0.18 | -0.23 |
| % Growth | 24.9% | 38.9% | 21.7% | – |
| EPS Diluted | -0.083 | -0.11 | -0.18 | -0.23 |
| Weighted Avg Shares Out | 14 | 14 | 13 | 13 |
| Weighted Avg Shares Out Dil | 14 | 14 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$1 | -$0 | -$2 |
| EBITDA | $1 | -$3 | -$3 | -$5 |
| % Margin | – | – | – | – |